http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
인터넷 쇼핑몰을 통한 國內 貴金屬ㆍ寶石 구매 실태와 효율적 운영 方案에 관한 硏究
유영효(Young-Hyo Yoo) 산업기술교육훈련학회 2008 산업기술연구논문지 (JITR) Vol.12 No.4
The market scale of jewelry and gems industry in Korea is currently presumed about 4 trillions to 4.5 trillions. The e-commerce has been spreading rapidly. As for the circulation markets, it appears as a trend to purchase jewelry products through the internet shopping mall within various price level. Only 2 or 3 years ago, the e-commerce industry in Korea was in very week condition, however, currently there are more than 3000 internet shopping malls in Korea. After 2 or 3 years from now, there will be more demands for jewelry through internet shopping malls, and thus the domestic jewelry internet shopping malls are expected to grow in large. But the internet shopping mall has many problems in shipping, payment, and refund. Even though the internet shopping mall, the new circulation process of the information-oriented era, has been raised many questions in management, there is a lack of study that grasp the management conditions and problems, and provide the improvement scheme. Therefore, this study will provide improvement scheme after figuring out the problems of internet shopping mall by analyzing the actual conditions of shopping mall management in domestic jewelry market.
신규 플르오로퀴놀론계 항생물질인 DWP20373 의 흰쥐 및 개에서의 체내동태와 조직분포
심점순(Jeom Soon Shim),유영효(Young Hyo Yu),남권호(Kweon Ho Nam),박명환(Myung Hwan Park),공재양(Jae Yang Kong),조재열(Jae Youn Cho),한승희(Seung Hee Han),김병오(Byoung O Kim),김지연(Ji Yeon Kim),유은숙(Eun Sook Yoo),정대영(Dae Young 한국응용약물학회 1997 Biomolecules & Therapeutics(구 응용약물학회지) Vol.5 No.2
The pharmacokinetics and tissue distribution of DWP20373, a novel fluoroquinolone, were examined in rats and beagle dogs after a single intravenous and oral administration. Analysis of DWP20373 in plasma, tissue, and urine was performed by both HPLC and microbiological assay. The plasma drug concentration declined biexponentially both rats and beagle dogs. In the rats, the terminal drug elimination half-life (t_(½β)) was 64 min (IV) and 57 min (PO) by bioassay, and 76 min (IV) and 77 min (PO) by HPLC. Whereas, in beagle dogs, t_(½β) was 196 min (IV) and 350 min (PO). The volume of distribution at steady-state (Vd_(ss)) was 811 ml/kg (bioassay) and 2061 ml/kg (HPLC) in rats, and 2738 ml/kg (bioassay) in beagle dogs. The total body clearance (Cl₁) of DWP20373 was 10 ml/min/kg (bioassay) and 7 ml/min/kg (HPLC) in rats, and 11 ml/min/kg (bioassay) in beagle dogs. The extent of bioavailability after oral administration was 49% (bioassay) and 67% (HPLC) in rats, and 84% (bioassay) in beagle dogs. The 24-h urinary recovery, measured by bioassay, was 2.7% after oral dosing and 5.5% after intravenous dosing in rats. Serum protein binding ratio determined at 2 ㎍/㎖ was 78%. This drug was also distributed in tissues in the decreasing order of liver, kidney, spleen, lung, heart, and muscle determined at 30 min after oral administration.
흰쥐의 만성궤양 모델에서 Aceglutamide aluminium를 함유한 복합제산제의 점막방어인자 증강작용
장병수(Byeong Su Jang),유은주(Eun Ju Yoo),박준우(Joon Woo Park),유영효(Young Hyo Yu),박명환(Myung Hwan Park) 대한약학회 1994 약학회지 Vol.38 No.6
Antacid(AM, 600mg/kg=aluminium hydroxide, magnesium hydroxide, and simethicone with a ratio of 1 : 1 : 0.1) and aceglutamide aluminium(AGA, 263 mg/kg)-Effect of the combined preparation containing on the gastric mucosal hexosamine, sialic acid, and aluminium contents adhered to the gastric wall of the rat was investigated. Severe ulcers were produced in rats by injecting of 30mcl acetic acid(30%) into the subserosal layer of one position in the corpus. When given orally for 15 consecutive days, AM(1,200mg/kg), AGA(525, 1,050mg/kg), and the combined preparation significantly decreased the ulcer area. AGA(525, 1,050mg/kg) and the combined preparation also increased the amount of hexosamine and sialic acid in the intact and ulcerated areas. On the other hand, the contents of hexosamine and sialic acid were not affected by AM (600, 1,200mg/kg). The amount of aluminium adhered to the gastric wall of the rat was higher in the combined preparation when compared to the AM(600mg/kg) and AGA(263mg/kg). The aluminium contents adhered may play an important role protecting mucosa from aggresive action of gastric juice and patenting defensive factors through the increase of mucosa-forming components by AGA.
흰쥐에 재조합 인간 상피세포 성장인자(DWP401)를 연용피하투여했을 때 약물체내동태
남권호(Kweon Ho Nam),조재열(Jae Youl Cho),정주영(Joo Young Chung),장우익(Woo Ik Chang),강진석(Jin Seok Kang),유은숙(Eun Sook Yoo),박승국(Seung Kook Park),유영효(Young Hyo Yu),박명환(Myung Hwan Park),심창구(Chang Koo Shim) 대한약학회 1996 약학회지 Vol.40 No.5
The organ distribution and pharmacokinetics of DWP401, a recombinant human epidermal growth factor (rhEGF), were compared after single and repeated subcutaneous administration (50mcg/kg, 10mcCi/kg of 125I-DWP401, twice a day for 7 consecutive days) to rats. The pharmacokinetic parameters such as AUC and terminal half-life were similar between two different administration. During repeated administration, the plasma concentration of DWP401 seemed to be constant when the plasma was collected at 15 min after each dosing. The TCA-precipitated radioactivities in thyroid, liver, kidney, and stomach were higher than those of other organs studied after both single and repeated administration. The TCA-precipitated radioactivities after repeated administration in several organs, such as thyroid, stomach, prostate, adrenal, eye ball, and testis were higher than those after single administration. But, according to the observations using gel filtration chromatography and antibody binding assay, the radioactivities in thyroid and stomach were not primarily due to the intact DWP401 or its metabolites but due to the 125I-thyroxine binding protein. In conclusion, it can be suggested that DWP401 is metabolized to each amino acid or small polypeptides, and there was no significant changes in pharmacokinetics or any indications for accumulation of DWP401 in rat plasma and organs after repeated treatment.
흰쥐에서 제산제와 병용투여된 아세글루타미드 알루미늄의 약물동태 및 위장관 부착
조재열(Jae Youl Cho),남권호(Kweon Ho Nam),유은숙(Eun Sook Yoo),유영효(Young Hyo Yu),박명환(Myung Hwan Park),박정일(Jeong Hill Park) 대한약학회 1995 약학회지 Vol.39 No.6
On the combination of antacid, the pharmacokinetics and gastric adhesion of [14C]aceglutamide aluminium complex([14C]AGA) were examined in rats. Specially, this study was focused on the drug interaction that the co-administration of anatacid may affect the oral co-administration of [14C] AGA and antacid(aluminium hydroxide and magnesium hydroxide(AM)), the radioactivity of plasma and urinary recovery was lower than that of [14C]AGA alone administered group. However, the cumulative recovery of radioactivity in feces was increased significantly. The comparative bioavailability of [14C]AGA from the plasma concentration-time curve and urinary recovery was about 60%. In vitro, the effect of antacid on the gastric adhesion of AGA was not significantly different between AGA and AGA/antacid treatment. And it accorded well with the result of in vivo experiment. In conclusion, on the combination of antacid , the oral absorption of AGA was decreased but the gastric adhesion was not affected in respect of drug interaction.
C7위치에 3-아미노-4-메칠치오메칠피로리디닐기를 치환한 신규 퀴놀론계 항생물질 DWP10349 및 DWP20351의 흰쥐에서의 체내동태 및 조직분포
조재열(Jae Youl Cho),남권호(Kweon Ho Nam),유은숙(Eun Sook Yoo),이재욱(Jae Wook Lee),유영효(Young Hyo Yu),박명환(Myung Hwan Park) 대한약학회 1997 약학회지 Vol.41 No.3
Pharmacokinetics and tissue distribution of DWP20349 and 20351, new quinolones, were examined in rats after a single intravenous and oral administration. Analyses of DWP20349 and DWP20351 in plasma, tissue, and urine were determined by both HPLC and bioassay(microbiological assay). The plasma concentrations of the drugs declined biexponentially. The terminal half-lives (t1/2beta) of drugs were about 114 min (DWP20349) and 105 min (DWP20351) after intravenous dosing, and were 77 min (DWP20349) and 79 min (DWP20351) after oral dosing. The volume of distrbution at steady-state (Vdss) and total body clearances (Clt) of DWP20349 and DWP20351 were 760 ml/kg and 1126 ml/kg, and 5ml/min/kg and 10 ml/min/kg, respectively. The extents of bioavailability if DWP20349 and DWP20351 after oral administration were 29% and 28%, respectively. 24 h urinary recoveries measured by bioassay were 1.8% (DWP20349) and 1.3% (DWP20351) after oral dosing, and 2.4% (DWP20349) and 1.9% (DWP20351) after intravenous dosing. Plasma protein binding ratios ranged from 87%-90% (DWP20349) and 61%-68% (DWP20351). These drugs were highly distrbuted by the order of lung, kidney, liver and plasma (DWP20394), and lung, liver, kidney and plasma (DWP20351) after 1 hour orally administered.
흰쥐에서 UDCA와 Silymarin을 함유한 간장질환 치료용 의약조성물(DWP305)의 담즙 및 요중 배설
남권호(Kweon Ho Nam),김동오(Dong O Kim),조재열(Jae Youl Cho),염제호(Je Ho Yeom),김영만(Young Man Kim),유은숙(Eun Sook Yoo),유영효(Young Hyo Yu),박명환(Myung Hwan Park) 대한약학회 1994 약학회지 Vol.38 No.6
The pharmacokinetics of DWP305, a new combined preparation for hepatic disorders was examined in rats. DWP305 was composed of ursodeoxycholic acid(UDCA), Cardus marianus extract(silymarin 74.5%), fursulthiamine and riboflavin tetrabutyrate(RTB). Especially, this study was focused on, the possibilities of drug interaction that the administration of DWP305 may affect the oral absorption of each component. After oral administration of DWP305 and each component drug to rats, the biliary excretion of silybin and tauroursodeoxycholic acid(TLJDCA), and the urinary excretion of vitamins were measured by HPLC up to 48 hours. The cumulative amount of TLTDCA or silybin in bile was not significantly different between DWP305 and UDCA/silymarin administered groups at doses of 25 and 100mg/kg. In the case of vitamin study, the urinary thiamine excretion of equivalent molar fursulthiamine administered group was significantly higher than that of thiamine administered group. Urinary riboflavin level of equivalent molar RTB administered group was lower than that of riboflavin administered group, but not significant. These results suggest that the combined preparation may not affect the oral absorption of each component in respect of drug in teraction. Also, fursulthiamine and RTB were more effective in oral absorption than thiamine and riboflavin, respectively.
흰쥐에서 Ursodeoxycholic Acid 및 Silymarin을 함유한 의약조성물(DWP305)의 연용투여에 의한 간내 담즙산 조성변화
조재열(Jae Youl Cho),연제덕(Je Deuk Yeon),남권호(Kweon Ho Nam),김점용(Jeum Yong Kim),유은숙(Eun Sook Yoo),유영효(Young Hyo Yu),박명환(Myung Hwan Park) 대한약학회 1996 약학회지 Vol.40 No.3
DWP305, a preparation containing combination of ursodeoxycholic acid(UDCA), silymarin and vitamins (B1 and B2), is a drug currently being developed for hepatic disorders. In order to evaluate the changes in hepatic function by multiple oral administration(2 and 4 weeks) of DWP305 in rats, several biochemical parameters in blood, bile acid composition, and the accumulation of UDCA and lithocholic acid(LCA),a toxic metabolite formed by enterobacteria, were examined using HPLC. In blood biochemical findings, DWP305 did not affect the normal level and there was no difference in total bile acid composition for UDCA, cholic acid(CA), deoxycholic acid(DCA), chenodeoxycholic acid(CDCA) and LCA compared to the UDCA administered group, although total ratio of UDCA and CA was different from normal group. In case of ratio of taurine and glycine conjugated forms, DWP305(186mg/kg as a UDCA) administered group was also similar to normal group and UDCA administered group, while high dosing of DWP305 was not different in the ratio of UDCA administered group(930mg/kg) but normal group. And the ratio of LCA was in order of UDCA(930mg/kg), DWP305(930mg/kg as a UDCA), UDCA(186mg/kg) and DWP305(186mg/kg as a UDCA) administered group, which was less than 4%. The free form of UDCA as well as most of bile acids was not detected at all in rat liver, indicating that there''s no accumulation. These results suggest that multiple dosing of DWP305 in rats may not affect hepatic biotransformation and metabolism of bile acids.